Perform Another (Advanced) Search

1.  Study Posting (1918) Trial #158901, Leukemia, Savannah, GA
...acute lymphoblastic leukemia. • Patient must have either systemic hypersensitivity reactions to native (Elspar) or pegylated E.coli asparaginase (Oncaspar). This includes patients with generalized rash with or without anaphylactic symptoms, or patients ...
View Page

2.  Newly Approved Drug Therapies (107) Cipro (ciprofloxacin HCl), Bayer,
...cystitis General Information Cipro has been approved as treatment for acute, uncomplicated cystitis, caused by E.coli or Staphylococcus saprophyticus. Cystitis is one of the most common urinary tract infections (UTI) in ...
View Page

3.  Newly Approved Drug Therapies (978) Accretropin (somatropin rDNA Original), Cangene Corp,
...human growth hormone product. This protein is produced by recombinant DNA technology during fermentation in E. coli, yielding a protein containing 192 amino acids. The N-terminal amino acid, methionine, is later ...
View Page

4.  Newly Approved Drug Therapies (207) Cipro (ciprofloxacin) I.V. and Cipro (ciprofloxacin HCI) tablets, Bayer,
...for use in combination with metronidazole, for treatment of complicated intra-abdominal infections caused by E. coli, Pseudomonas aeruginosa, Proteus mirabilis, Klebsiella pneumoniae, or Bacteroides fragilis. This study showed that conversion to ...
View Page

5.  News: Terrifying Budget Numbers (Clinical Trials Today)
...the American people from terrorist threats against our food and drug supply. With the latest E. coli scare in the news, it became clear that the FDA does not have the resources ...
View Page

6.  Newly Approved Drug Therapies (597) Tequin, Bristol-Myers Squibb,
...pneumonia Other indications include: • Uncomplicated urinary tract infections (cystitis) • Complicated urinary tract infections • Pyelonephritis (from e.Coli) • Uncomplicated urethral and cervical gonorrhea • Acute, complicated rectal infections in women Clinical Results Tequin has ...
View Page

7.  CenterWatch: New Medical Therapies in Disease Category (289), Chronic Diarrhea
...received three doses of the vaccine or placebo and were then given a dose of E. coli larger than would be expected under natural conditions. Both groups met the definition of moderate ...
View Page

8.  Study Posting (4519) Trial #104870, Non-Hodgkin's Lymphoma, Tepic, Mexico
...0-2. Exclusion Criteria: • any premalignant myeloid condition; • bone marrow involvement; • hypersensitivity reactions to other E. coli products; • active infections requiring the use of systemic ant-infective therapies. Gender: Males or Females ...
View Page

9.  Study Posting (4519) Trial #103600, Non-Hodgkin's Lymphoma, Puebla, Mexico
...0-2. Exclusion Criteria: • any premalignant myeloid condition; • bone marrow involvement; • hypersensitivity reactions to other E. coli products; • active infections requiring the use of systemic ant-infective therapies. Gender: Males or Females ...
View Page

10.  Study Posting (4519) Trial #112077, Non-Hodgkin's Lymphoma, Obregon, Mexico
...0-2. Exclusion Criteria: • any premalignant myeloid condition; • bone marrow involvement; • hypersensitivity reactions to other E. coli products; • active infections requiring the use of systemic ant-infective therapies. Gender: Males or Females ...
View Page

11.  Study Posting (4519) Trial #98681, Non-Hodgkin's Lymphoma, Mexico City, Mexico
...0-2. Exclusion Criteria: • any premalignant myeloid condition; • bone marrow involvement; • hypersensitivity reactions to other E. coli products; • active infections requiring the use of systemic ant-infective therapies. Gender: Males or Females ...
View Page

12.  Study Posting (4519) Trial #96789, Non-Hodgkin's Lymphoma, Leon, Mexico
...0-2. Exclusion Criteria: • any premalignant myeloid condition; • bone marrow involvement; • hypersensitivity reactions to other E. coli products; • active infections requiring the use of systemic ant-infective therapies. Gender: Males or Females ...
View Page

13.  Study Posting (4519) Trial #106644, Non-Hodgkin's Lymphoma, Guadalajara, Mexico
...0-2. Exclusion Criteria: • any premalignant myeloid condition; • bone marrow involvement; • hypersensitivity reactions to other E. coli products; • active infections requiring the use of systemic ant-infective therapies. Gender: Males or Females ...
View Page

14.  Study Posting (4519) Trial #154014, Non-Hodgkin's Lymphoma, Estado De Mexico, Mexico
...0-2. Exclusion Criteria: • any premalignant myeloid condition; • bone marrow involvement; • hypersensitivity reactions to other E. coli products; • active infections requiring the use of systemic ant-infective therapies. Gender: Males or Females ...
View Page

15.  Study Posting (4519) Trial #99049, Non-Hodgkin's Lymphoma, Chihuahua, Mexico
...0-2. Exclusion Criteria: • any premalignant myeloid condition; • bone marrow involvement; • hypersensitivity reactions to other E. coli products; • active infections requiring the use of systemic ant-infective therapies. Gender: Males or Females ...
View Page

16.  Study Posting (4519) Trial #101967, Non-Hodgkin's Lymphoma, Bogota, Colombia
...0-2. Exclusion Criteria: • any premalignant myeloid condition; • bone marrow involvement; • hypersensitivity reactions to other E. coli products; • active infections requiring the use of systemic ant-infective therapies. Gender: Males or Females ...
View Page

17.  Study Posting (4519) Trial #102795, Breast Cancer, Toluca, Mexico
...30 days of study start; • bone marrow diseases; • previous allergic reactions to GSFs or other E. coli products; • active infections requiring use of antibiotics within 7 days of study start. Gender: Females ...
View Page

18.  Study Posting (4519) Trial #106699, Breast Cancer, Tijuana, Mexico
...30 days of study start; • bone marrow diseases; • previous allergic reactions to GSFs or other E. coli products; • active infections requiring use of antibiotics within 7 days of study start. Gender: Females ...
View Page

19.  Study Posting (4519) Trial #103598, Breast Cancer, Puebla, Mexico
...30 days of study start; • bone marrow diseases; • previous allergic reactions to GSFs or other E. coli products; • active infections requiring use of antibiotics within 7 days of study start. Gender: Females ...
View Page

20.  Study Posting (4519) Trial #99972, Breast Cancer, Monterrey, Mexico
...30 days of study start; • bone marrow diseases; • previous allergic reactions to GSFs or other E. coli products; • active infections requiring use of antibiotics within 7 days of study start. Gender: Females ...
View Page